Structure-based design technology contour and its application to the design of renin inhibitors

Journal of Chemical Information and Modeling

Volumn 52, Issue 8, 2012, Pages 2089-2097

  Ishchenko, Alexey ^a   Liu, Zhijie ^a   Lindblom, Peter ^a   Wu, Guosheng ^a   Jim, Kam Chuen ^a   Gregg, Richard D ^a   Claremon, David A ^a   Singh, Suresh B ^a  

^a Vitae Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BIOCHEMISTRY; CRYSTAL STRUCTURE; MOLECULES; PROTEINS;

BINDING INTERACTION; CONFORMATIONAL SPACE; DRUG DISCOVERY PROCESS; ESSENTIAL ELEMENTS; HIGH RESOLUTION CRYSTAL STRUCTURE; PROTEIN-BINDING SITES; STRUCTURE-BASED DESIGNS; THERAPEUTIC AGENTS;

STRUCTURAL DESIGN;

PROTEINASE INHIBITOR; RENIN;

ALGORITHM; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; PROTEIN CONFORMATION; REPRODUCIBILITY;

ALGORITHMS; BINDING SITES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PROTEASE INHIBITORS; PROTEIN CONFORMATION; RENIN; REPRODUCIBILITY OF RESULTS;

EID: 84865517667     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci200605k     Document Type: Article

References (34)

1. Drews, J. Drug discovery: a historical perspective Science 2000, 287, 1960-1964 (Pubitemid 30158662)
2. Gershell, L. J.; Atkins, J. H. A brief history of novel drug discovery technologies Nat. Rev. Drug Discovery 2003, 2, 321-327 (Pubitemid 37361690)
3. Abola, E.; Calrton, D. D.; Kuhn, P.; Stevens, R. C. Five years of increasing structural biology throughput-A retrospective analysis. In Structrure Based Discovery, 1 st ed.; Harren, J.; Leach, A. R., Eds.; Springer: Dordrecht, The Netherlands, 2007; Vol. 1, pp 1-24.
4. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
5. Böhm, H. J. Prediction of Non-bonded Interactions in Drug Design; Wiley-VCH Verlag GmbH & Co. KGaA: New York, 2006; pp 3-20.
6. Williams, M. A.; Ladbury, J. E. Hydrogen Bonds in Protein-Ligand Complexes; Wiley-VCH Verlag GmbH & Co. KGaA: New York, 2005; pp 137-161.
7. Böhm, H.-J.; Schneider, G. Protein-Ligand Interactions: From Molecular Recognition to Drug Design; Wiley-VCH Verlag GmbH & Co. KGaA: New York, 2006; p 262.
8. Danziger, D. J.; Dean, P. M. Automated site-directed drug design: the prediction and observation of ligand point positions at hydrogen-bonding regions on protein surfaces Proc. R. Soc. London, Ser. B 1989, 236, 115-124 (Pubitemid 19085345)
9. Moon, J. B.; Howe, W. J. Computer design of bioactive molecules: A method for receptor-based de novo ligand design Proteins: Struct., Funct., Bioinf. 1991, 11, 314-328
10. Appelt, K.; Bacquet, R. J.; Bartlett, C. A.; Booth, C. L. J.; Freer, S. T.; Fuhry, M. A. M.; Gehring, M. R.; Herrmann, S. M.; Howland, E. F. Design of enzyme inhibitors using iterative protein crystallographic analysis J. Med. Chem. 1991, 34, 1925-1934
11. Bohacek, R. S.; McMartin, C. Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth J. Am. Chem. Soc. 1994, 116, 5560-5571
12. Rotstein, S. H.; Murcko, M. A. GenStar: A method for de novo drug design J. Comput.-Aided Mol. Des. 1993, 7, 23-43
13. Gillet, V. J.; Newell, W.; Mata, P.; Myatt, G.; Sike, S.; Zsoldos, Z.; Johnson, A. P. SPROUT: Recent developments in the de novo design of molecules J. Chem. Inf. Model. 1994, 34, 207-217
14. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design J. Comput.-Aided Mol. Des. 1997, 11, 333-344 (Pubitemid 127506740)
15. Ripka, A. S.; Bohacek, R. S.; Rich, D. H. Synthesis of novel cyclic protease inhibitors using Grubbs olefin metathesis Bioorg. Med. Chem. Lett. 1998, 8, 357-360 (Pubitemid 28072706)
16. Wang, R.; Gao, Y.; Lai, L. LigBuilder: a multi-purpose program for structure-based drug design J. Mol. Model. 2000, 6, 498-516
17. Grzybowski, B. A.; Ishchenko, A. V.; Shimada, J.; Shakhnovich, E. I. From knowledge-based potentials to combinatorial lead design in silico Acc. Chem. Res. 2002, 35, 261-269
18. Shimada, J. The challenges of making useful protein-ligand free energy predictions for drug discovery. In Computer Applications in Pharmaceutical Research and Development; Ekins, S., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2006; pp 321-351.
19. Jorgensen, W. L.; Ruiz-Caro, J.; Tirado-Rives, J.; Basavapathruni, A.; Anderson, K. S.; Hamilton, A. D. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 2006, 16, 663-667 (Pubitemid 43014855)
20. Kutchukian, P. S.; Shakhnovich, E. I. De novo design: balancing novelty and confined chemical space Expert Opin. Drug Discovery 2010, 5, 789-812
21. Bajorath, J.; Hartenfeller, M.; Schneider, G. De novo drug design. Chemoinformatics and Computational Chemical Biology; Humana Press: Totowa, NJ, 2011; Vol. 672, pp 299-323.
22. Atlas, S. A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition J. Manag. Care Pharm. 2007, 13, S9-S20
23. Tyndall, J. D. A.; Nall, T.; Fairlie, D. P. Proteases universally recognize beta strands in their active sites Chem. Rev. 2005, 105, 973-1000
24. CHARMM, Version 27; Accelrys, Inc.: San Diego, CA, 2007.
25. Comprehensive Medicinal Chemistry Database; Accelrys, Inc.: San Diego, CA, 2003.
26. Bohacek, R. Boston Denovo Design. Personal communication.
27. Irwin, J. J.; Shoichet, B. K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2004, 45, 177-182 (Pubitemid 40736970)
28. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules J. Am. Chem. Soc. 1995, 117, 5179-5197
29. Allen, F. The Cambridge Structural Database: a quarter of a million crystal structures and rising Acta Crystallogr., Sect. B: Struct. Sci. 2002, 58, 380-388 (Pubitemid 135702674)
30. Rahuel, J.; Priestle, J. P.; Grütter, M. G. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor J. Struct. Biol. 1991, 107, 227-236
31. Tice, C. M.; Xu, Z.; Yuan, J.; Simpson, R. D.; Cacatian, S. T.; Flaherty, P. T.; Zhao, W.; Guo, J.; Ishchenko, A.; Singh, S. B.; Wu, Z.; Scott, B. B.; Bukhtiyarov, Y.; Berbaum, J.; Mason, J.; Panemangalore, R.; Cappiello, M. G.; Müller, D.; Harrison, R. K.; McGeehan, G. M.; Dillard, L. W.; Baldwin, J. J.; Claremon, D. A. Design and optimization of renin inhibitors: Orally bioavailable alkyl amines Bioorg. Med. Chem. Lett. 2009, 19, 3541-3545
32. Xu, Z.; Cacatian, S.; Yuan, J.; Simpson, R. D.; Jia, L.; Zhao, W.; Tice, C. M.; Flaherty, P. T.; Guo, J.; Ishchenko, A.; Singh, S. B.; Wu, Z.; McKeever, B. M.; Scott, B. B.; Bukhtiyarov, Y.; Berbaum, J.; Mason, J.; Panemangalore, R.; Cappiello, M. G.; Bentley, R.; Doe, C. P.; Harrison, R. K.; McGeehan, G. M.; Dillard, L. W.; Baldwin, J. J.; Claremon, D. A. Optimization of orally bioavailable alkyl amine renin inhibitors Bioorg. Med. Chem. Lett. 2011, 20, 694-699
33. Jia, L.; Simpson, R. D.; Yuan, J.; Xu, Z.; Zhao, W.; Cacatian, S.; Tice, C. M.; Guo, J.; Ishchenko, A.; Singh, S. B.; Wu, Z.; McKeever, B. M.; Bukhtiyarov, Y.; Johnson, J. A.; Doe, C. P.; Harrison, R. K.; McGeehan, G. M.; Dillard, L. W.; Baldwin, J. J.; Claremon, D. A. Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility ACS Med. Chem. Lett 2011, 2, 747-751
34. Pipeline Pilot, Version 8.5; Accelrys Inc.: San Diego, CA, 2012.